NCT00561236

Brief Summary

The use of intravitreal corticosteroids in the management ocular inflammatory diseases has recently gained widespread acceptance. The purpose of this study is to determine if the use of intravitreal triamcinolone is associated with suppression of endogenous cortisol production, as generally admitted for patients treated with oral or parenteral corticosteroid therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2007

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2007

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

November 18, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 20, 2007

Completed
11 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2008

Completed
Last Updated

September 8, 2016

Status Verified

September 1, 2016

Enrollment Period

8 months

First QC Date

November 18, 2007

Last Update Submit

September 7, 2016

Conditions

Secondary Adrenal Insufficiency

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

hospital-based ophtalmologic clinic

You may qualify if:

  • patients receiving intravitreous injection of triamcinolone 4mg

You may not qualify if:

  • patients receiving steroids in any form, except by intravitreous administration

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Haemek Medical Center

Afula, 18101, Israel

Location

Study Officials

  • Avraham Ishay, MD

    Haemek Medical Center , Endocrine Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

November 18, 2007

First Posted

November 20, 2007

Study Start

April 1, 2007

Primary Completion

December 1, 2007

Study Completion

January 1, 2008

Last Updated

September 8, 2016

Record last verified: 2016-09

Data Sharing

IPD Sharing
Will not share

Locations

IL(1)